May 28, 2026 — Australian superannuation giant HESTA has emerged as the cornerstone investor in a new venture capital initiative targeting early-stage health and medical technology startups.
The debut fund, launched by Synthesis Capital, has already secured close to $60 million in commitments and is on track to reach its $70 million target. The raise has drawn support not only from HESTA but also from family offices, global health industry executives, and the Menzies Leadership Foundation.
After two years of preparation, the fund is positioned to back innovative Australian med‑tech ventures at the earliest stages of growth. By channeling capital into health technology, Synthesis Capital aims to accelerate breakthroughs that can strengthen patient care and drive long-term industry transformation.
This move underscores the growing role of institutional investors in fueling the next wave of medical innovation, with HESTA’s participation signaling confidence in the sector’s potential to deliver both impact and returns.
